Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

791
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
791
Rational Emotive Behavior Therapy01:24

Rational Emotive Behavior Therapy

340
Cognitive-behavioral therapies (CBTs) are grounded in the belief that our thoughts profoundly influence our emotions and actions. Advocates of CBT emphasize three core assumptions: first, that cognitions are identifiable and measurable; second, that they are central to psychological functioning; and third, that irrational or maladaptive beliefs can be replaced with rational and adaptive ones. This transformative approach to therapy has paved the way for specific models such as Albert...
340
Borderline Personality Disorder01:25

Borderline Personality Disorder

511
Borderline Personality Disorder is a complex and multifaceted mental health condition characterized by pervasive instability in interpersonal relationships, self-image, emotions, and impulse control. This instability manifests in extreme emotional reactions, fear of abandonment, and self-destructive behaviors. The disorder significantly impacts daily functioning, often leading to distress in both personal and professional domains.
Genetic and Environmental Contributions
Borderline Personality...
511
Electroconvulsive Therapy01:30

Electroconvulsive Therapy

841
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
841
Behavior Therapy01:22

Behavior Therapy

597
Behavior therapy incorporates diverse techniques rooted in classical conditioning principles to address maladaptive behaviors and anxiety disorders. These methods aim to reduce avoidance behaviors, foster adaptive coping mechanisms, and alter associations between stimuli and responses, making them effective in a wide range of therapeutic contexts.
Exposure therapy is a cornerstone of behavioral treatment for anxiety disorders. It involves systematic exposure to feared stimuli, either in real...
597
Drug Therapy01:28

Drug Therapy

237
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
237

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Identifying suicide-related language in smartphone keyboard entries among high-risk adolescents.

NPJ digital medicine·2026
Same author

Does Dialectical Behaviour Therapy for adolescents affect suicidal ideation and use of coping skills in adulthood? A 12.4-years follow-up study of a Randomized Trial using Ecological Momentary Assessment.

Behaviour research and therapy·2026
Same author

Elevated serotonin 1A receptor binding in borderline personality disorder co-morbid with major depressive episodes appears attributable to major depression alone.

Journal of psychiatric research·2026
Same author

Differentiating Suicide Attempt History Among Individuals with Borderline Personality Disorder Engaging in Non-Suicidal Self-Injury.

Archives of suicide research : official journal of the International Academy for Suicide Research·2026
Same author

Challenges of Suicide Prevention in Children: A Thematic Analysis of Clinician Insights.

Archives of suicide research : official journal of the International Academy for Suicide Research·2026
Same author

Antidepressant retention and adherence among Latinx outpatients with major depressive disorder: The effect of a novel motivational interviewing-consistent approach to pharmacotherapy.

Journal of affective disorders·2026

Related Experiment Video

Updated: Jan 12, 2026

The Forced Swim Test as a Model of Depressive-like Behavior
05:42

The Forced Swim Test as a Model of Depressive-like Behavior

Published on: March 2, 2015

39.6K

Dialectical Behavior Therapy Versus Serotonin Reuptake Inhibitor Treatment for Suicidal Behavior in Borderline

Beth S Brodsky1,2, Hanga Galfalvy2,3, J John Mann1,2

  • 1Molecular Imaging and Neuropathology Division, New York State Psychiatric Institute, New York.

The American Journal of Psychiatry
|November 5, 2025
PubMed
Summary

Dialectical behavior therapy (DBT) significantly reduced suicide-related events (SREs) and nonsuicidal self-injury (NSSI) in borderline personality disorder patients more effectively than selective serotonin reuptake inhibitors with clinical management (SSRI/M). Outcomes were comparable at 12 months.

Keywords:
Borderline Personality DisorderDialectical Behavior TherapyNonsuicidal Self-InjurySSRISuicide Attempt

More Related Videos

Individualized rTMS Treatment for Depression using an fMRI-Based Targeting Method
07:12

Individualized rTMS Treatment for Depression using an fMRI-Based Targeting Method

Published on: August 2, 2021

4.1K
MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder
08:20

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder

Published on: August 11, 2015

14.5K

Related Experiment Videos

Last Updated: Jan 12, 2026

The Forced Swim Test as a Model of Depressive-like Behavior
05:42

The Forced Swim Test as a Model of Depressive-like Behavior

Published on: March 2, 2015

39.6K
Individualized rTMS Treatment for Depression using an fMRI-Based Targeting Method
07:12

Individualized rTMS Treatment for Depression using an fMRI-Based Targeting Method

Published on: August 2, 2021

4.1K
MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder
08:20

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder

Published on: August 11, 2015

14.5K

Area of Science:

  • Psychiatry
  • Clinical Psychology

Background:

  • Borderline personality disorder (BPD) is a complex mental health condition often associated with high rates of suicide-related events (SREs) and nonsuicidal self-injury (NSSI).
  • Effective treatment strategies for BPD are crucial for improving patient outcomes and reducing healthcare burdens.

Purpose of the Study:

  • To compare the efficacy of 6-month dialectical behavior therapy (DBT) versus 6-month selective serotonin reuptake inhibitors with clinical management (SSRI/M) in reducing SREs, suicide attempts, and NSSI in individuals with BPD.
  • To evaluate related clinical outcomes, including depression severity and suicidal ideation, in patients with BPD.

Main Methods:

  • A randomized controlled trial involving 84 individuals diagnosed with BPD and a history of recent SREs or NSSI.
  • Participants were assigned to either DBT or SSRI/M for 6 months.
  • Statistical analyses included Poisson models, zero-inflated Poisson models, survival analysis, and mixed-effects regression.

Main Results:

  • The DBT group exhibited significantly fewer SREs and NSSI behaviors compared to the SSRI/M group during the 6-month treatment phase.
  • Survival analysis revealed a significantly lower risk of experiencing any SRE in the DBT group.
  • While depression and suicidal ideation severity decreased comparably in both groups, the SSRI/M group showed a lower rate of major depressive disorder post-treatment.

Conclusions:

  • Six months of DBT demonstrated superior efficacy over SSRI/M in reducing SREs and NSSI behaviors in patients with BPD.
  • Despite initial differences, treatment outcomes became comparable between DBT and SSRI/M at the 12-month follow-up.